HEBEI CHANGSHAN BIOCHEMICA

Hebei Changshan Biochemica: Flat Stock, Falling Fundamentals – Why Investors Must Caution

Hebei Changshan Biochemica’s flat price masks a 19% decline and low liquidity, warning investors about its declining fundamentals and unclear growth strategy.

HEBEI CHANGSHAN BIOCHEMICA
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Vanessa Liu

23/10/2026, 11:09

4 minutes to read

Hebei Changshan Biochemica: Flat Trading, EU DCP Milestone, Market Overview

Hebei Changshan Biochemica’s Enoxaparin sodium injection clears EU DCP in Croatia—potential EU-wide approval, but limited short‑term revenue impact.

HEBEI CHANGSHAN BIOCHEMICA
China
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Elliot Mercer

20/10/2026, 23:29

2 minutes to read